Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics
| Autor: | Nigora Rasulova, Kalevi Kairemo, Timo Joensuu, Timo Kiljunen, Aki Kangasmäki |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
lcsh:R5-920
Gamma imaging gamma imaging business.industry Clinical Biochemistry Alpha (ethology) Case Report radionuclide therapy prostate cancer medicine.disease Lesion Prostate cancer Gamma scintigraphy Pharmacokinetics Radionuclide therapy Medicine Dosimetry medicine.symptom lcsh:Medicine (General) business Nuclear medicine alpha-emitters |
| Zdroj: | Diagnostics, Vol 5, Iss 3, Pp 358-368 (2015) Diagnostics |
| ISSN: | 2075-4418 |
| DOI: | 10.3390/diagnostics5030358 |
| Popis: | Radium-223-dichloride (223RaCl2) is a new bone-seeking calcium analogue alpha-emitter, which has obtained marketing authorization for the treatment skeletal metastases of hormone-refractory prostate cancer. The current treatment regimen is based on six consecutive doses of 223RaCl2 at 4 week intervals and the administered activity dose, 50 kBq/kg per cycle is based on patient weight. We analyzed two patients using quantitative serial gamma imaging to estimate dosimetry in tumors and see possible pharmacokinetic differences in the treatment cycles. The lesions were rather well visualized in gamma scintigraphy in spite of low gamma activity ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|